Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iberdomide Maintenance Therapy for Multiple Myeloma Post-AHCT
NCT05354557Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2022
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of iberdomide in multiple myeloma (MM), sponsored by Memorial Sloan Kettering Cancer Center. Started Apr 2022; status: active, not recruiting.
02
Drugs
iberdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05354557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05354557.